Overview

Corporate Profile

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit  www.t2biosystems.com.
Stock Quote
TTOO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.87
Change (%) Stock is Down 0.13 (3.25%)
Volume1,630,332
Data as of 06/23/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
06/19/17T2 Biosystems Chief Scientific Officer Tom Lowery to Present at BIO 2017 Convention
Panel to Discuss Use of Novel Diagnostic Technologies to Improve Patient Care and Aid in Management of Antimicrobials LEXINGTON, Mass., June 19, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that its chief scientific officer, Tom Lowery, Ph.D. is scheduled to present at the 2017 BIO International Convention in San Diego, CA as part of a session titled “Using Novel D... 
Printer Friendly Version
06/08/17T2 Biosystems to Present at the 2017 Marcum Microcap Conference
LEXINGTON, Mass., June 08, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that John McDonough, president and chief executive officer, and Darlene Deptula-Hicks, SVP and chief financial officer, are scheduled to attend and present at the 2017 Marcum Microcap Conference. The conference is being held June 15-16, 2017 at the Grand Hyatt Hotel in New York City. Manageme... 
Printer Friendly Version
06/07/17T2 Biosystems Announces New T2Sepsis Solution™ Clinical and Economic Results Presented by Leading Experts at ASM Microbe 2017 Conference
Clinical Experts Discuss T2BacteriaTM Early Experience and Potential Emergency Department Applications T2Candida® Panel Users Present Compelling Rationale for Adoption, Implementation Process, and the Positive Clinical and Economic Results LEXINGTON, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced new data on the company’s T2Sepsis Solution, which i... 
Printer Friendly Version
06/01/17Study Published in the Journal of Clinical Microbiology Highlights Detection of Lyme Disease-Causing Bacteria in Blood Using T2 Biosystems’ T2MR® Technology
Data show strong evidence that Lyme disease-causing bacteria exist in blood and that T2MR has superior sensitivity to conventional PCR methods for direct detection in blood. LEXINGTON, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that a new study, “T2 Magnetic Resonance-based Direct Detection of Three Lyme Disease-Related Borrelia Species in Whole B... 
Printer Friendly Version

More News

Investor Contact Information
Contact: ir@T2Biosystems.com
(781) 761-4646

Tucker Elcock, Teneo Strategy Tucker.Elcock@teneostrategy.com
(212) 886-9319

Data provided by Nasdaq. Minimum 15 minutes delayed.